A real-world pharmacovigilance study of netarsudil based on the FDA adverse event reporting system (FAERS)

Table 3 TTO of netarsudil-related AEs and Weibull distribution analysis

Cases number	TTO (days)	Weibull distribution				Failure type
	TTO (days)	Scale parameter		Shape parameter
	Median (IQR)	α	95% CI	β	95% CI
2138	1 (0–13)	50.12	45.23–55.01	0.82	0.75–0.89	Early failure

Abbreviations: AE, adverse event; CI, confidence interval; IQR, interquartile range; TTO, time to onset

ISSN: 2050-6511